Lexeo Therapeutics Cash Flow Statement (2022-2023) | LXEO

Cash Flow Statement Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023
Operating Activities
Net Income -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M
Share-based Compensation 0.43M0.52M0.40M0.97M0.87M0.80M
Gains from Investment Securities 0.04M0.11M0.11M0.10M0.11M0.10M
Non-cash Items 20.13M8.99M
Cash from Operations -16.63M-18.37M-13.19M-13.95M-13.98M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.05M0.30M0.32M0.08M0.08M0.33M
Depreciation & Amortization (CF) 0.06M0.06M0.06M0.08M0.08M
Change in Working Capital
Change in Account Payables -1.22M1.04M-1.91M0.29M0.39M
Change in Accured Expenses -0.91M-1.79M1.20M4.80M-2.12M
Change in Taxes 0.14M0.14M
Other Working Capital Changes 0.83M-0.52M-0.09M-0.48M-0.32M
Investing Activities
Capital Expenditures 0.03M0.01M0.04M0.02M0.04M
Cash from Investing Activities -0.11M-0.05M-0.07M
Financing Activities
Other financing activities 0.43M1.78M0.40M0.97M0.87M3.03M
Cash from Financing Activities -0.08M-0.10M-0.09M3.91M100.07M
Additional items
Change in Cash -16.81M-18.47M-13.32M-10.09M86.02M
Beginning Cash Balance 94.15M94.15M18.47M13.32M45.54M-86.02M
Free Cash Flow -16.65M-18.39M-13.23M-13.97M-14.02M
Net Cash Flow -16.81M-18.47M-13.29M-10.09M86.02M